Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.03
NYSE:GNC's Cash-to-Debt is ranked lower than
97% of the 373 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.54 vs. NYSE:GNC: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:GNC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.12 Max: N/A
Current: 0.03
Equity-to-Asset -0.03
NYSE:GNC's Equity-to-Asset is ranked lower than
98% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. NYSE:GNC: -0.03 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:GNC' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.05  Med: 0.28 Max: 0.42
Current: -0.03
-0.05
0.42
Piotroski F-Score: 4
Altman Z-Score: 1.81
Beneish M-Score: -3.56
WACC vs ROIC
4.05%
-16.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % -8.48
NYSE:GNC's Operating Margin % is ranked lower than
92% of the 373 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.88 vs. NYSE:GNC: -8.48 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:GNC' s Operating Margin % Range Over the Past 10 Years
Min: -8.48  Med: 13.63 Max: 17.62
Current: -8.48
-8.48
17.62
Net Margin % -12.45
NYSE:GNC's Net Margin % is ranked lower than
94% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.93 vs. NYSE:GNC: -12.45 )
Ranked among companies with meaningful Net Margin % only.
NYSE:GNC' s Net Margin % Range Over the Past 10 Years
Min: -12.45  Med: 6.39 Max: 10.09
Current: -12.45
-12.45
10.09
ROE % -193.49
NYSE:GNC's ROE % is ranked lower than
99% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.73 vs. NYSE:GNC: -193.49 )
Ranked among companies with meaningful ROE % only.
NYSE:GNC' s ROE % Range Over the Past 10 Years
Min: -193.49  Med: 15.97 Max: 35.82
Current: -193.49
-193.49
35.82
ROA % -13.19
NYSE:GNC's ROA % is ranked lower than
93% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.38 vs. NYSE:GNC: -13.19 )
Ranked among companies with meaningful ROA % only.
NYSE:GNC' s ROA % Range Over the Past 10 Years
Min: -13.19  Med: 5.45 Max: 10.02
Current: -13.19
-13.19
10.02
ROC (Joel Greenblatt) % -31.57
NYSE:GNC's ROC (Joel Greenblatt) % is ranked lower than
94% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.29 vs. NYSE:GNC: -31.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:GNC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -31.57  Med: 48.25 Max: 72.54
Current: -31.57
-31.57
72.54
3-Year Revenue Growth Rate 10.70
NYSE:GNC's 3-Year Revenue Growth Rate is ranked higher than
76% of the 338 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. NYSE:GNC: 10.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:GNC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 10.15 Max: 13.2
Current: 10.7
0
13.2
GuruFocus has detected 2 Warning Signs with GNC Holdings Inc $NYSE:GNC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:GNC's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 446199    SIC: 5912
Compare:OTCPK:ORIOY, OTCPK:PRCXF, NAS:PETS, OTCPK:COCP, NAS:CJJD, OTCPK:OMHE, OTCPK:HEWA, OTCPK:CLCGY, OTCPK:JCOUF, NYSE:RAD, OTCPK:RADLY, NAS:WBA » details
Traded in other countries:IGN.Germany,
Headquarter Location:USA
GNC Holdings Inc is a specialty retailer of health, wellness and performance products, including vitamins, minerals and herbal supplement products (VMHS), sports nutrition products and diet products.

GNC Holdings is a specialty retailer of health and wellness products that include vitamins, herbal supplements, sports nutrition products, and diet products. The company sells a broad range of nutritional products, including proprietary and third-party brands through three segments: retail, franchise, and manufacturing/wholesale (third party). Most of GNC's revenue is derived through the retail segment, where traditional shopping mall and strip shopping center locations generate a large percentage of the segment's sales.

Top Ranked Articles about GNC Holdings Inc

GNC Live Well Foundation Donates to Pittsburgh's Midtown Towers Fire Victims
Chuck Royce Continues to Buy These 10 Stocks Guru increased these holdings in the last 2 quarters
Chuck Royce (Trades, Portfolio) manages a portfolio composed of 1,116 stocks with a total value of $15.292 billion. In both the first quarter of 2017 and fourth-quarter 2016 the guru bought shares in the following stocks. Read more...
Mario Gabelli Continues to Buy These 9 Stocks Guru increased these holdings in the last 2 quarters
Mario Gabelli (Trades, Portfolio) is the founder, chairman and CEO of Gabelli Asset Management Co. Investors (GAMCO), a $30 billion global investment firm. In both the first quarter of 2017 and fourth-quarter 2016 the guru bought shares in the following stocks. Read more...
GNC Holdings, Inc. First Quarter 2017 Earnings Release, Webcast and Conference Call Scheduled for April 18, 2017
9 Stocks Mario Gabelli Continues to Buy The guru's largest purchases of the 3rd and 4th quarters
Mario Gabelli (Trades, Portfolio) is the founder, chairman and CEO of Gabelli Asset Management Co. Investors (GAMCO Investors) a $30 billion global investment firm headquartered in Rye, New York. He manages a portfolio composed of 816 stocks with a total value of $15.827 billion. In the third and fourth quarters of 2016 the guru bought shares in the following stocks: Read more...
Weekly CEO Buys Highlights Insiders invest in GNC, American Assets, CNA, PJT and OPKO
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
3 Undervalued Companies Where Bob Olstein Has Little-Known Activist Positions The market-beating leader in value investing is pushing for improved cash flow and market price
Widely followed investor Bob Olstein appeared on Fox Business last week to celebrate the rise this year of his undervalued stocks that languished last year, leading his all-cap value fund to a 16% gain and his small-cap fund to a 25% rise. Olstein, a quintessential value investor, also intervenes at usually smaller companies where he thinks management could unlock more value. This year, in a 10-year retrospective, he named some of them. Read more...
52-Week Company Lows Lows of 5 companies
According to the GuruFocus list of 52-week lows, these guru stocks have reached their 52-week lows. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 5.31
NYSE:GNC's Forward PE Ratio is ranked higher than
99% of the 67 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.76 vs. NYSE:GNC: 5.31 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PS Ratio 0.20
NYSE:GNC's PS Ratio is ranked higher than
75% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. NYSE:GNC: 0.20 )
Ranked among companies with meaningful PS Ratio only.
NYSE:GNC' s PS Ratio Range Over the Past 10 Years
Min: 0.18  Med: 1.44 Max: 2.3
Current: 0.2
0.18
2.3
Price-to-Free-Cash-Flow 11.38
NYSE:GNC's Price-to-Free-Cash-Flow is ranked higher than
73% of the 146 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.08 vs. NYSE:GNC: 11.38 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NYSE:GNC' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.74  Med: 18.14 Max: 34.58
Current: 11.38
3.74
34.58
Price-to-Operating-Cash-Flow 4.99
NYSE:GNC's Price-to-Operating-Cash-Flow is ranked higher than
82% of the 191 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.30 vs. NYSE:GNC: 4.99 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NYSE:GNC' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.63  Med: 13.88 Max: 25.35
Current: 4.99
2.63
25.35
Current Ratio 2.57
NYSE:GNC's Current Ratio is ranked higher than
88% of the 369 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.22 vs. NYSE:GNC: 2.57 )
Ranked among companies with meaningful Current Ratio only.
NYSE:GNC' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 3.06 Max: 3.91
Current: 2.57
2.21
3.91
Quick Ratio 0.64
NYSE:GNC's Quick Ratio is ranked lower than
59% of the 369 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.76 vs. NYSE:GNC: 0.64 )
Ranked among companies with meaningful Quick Ratio only.
NYSE:GNC' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.22 Max: 1.85
Current: 0.64
0.64
1.85
Days Inventory 129.29
NYSE:GNC's Days Inventory is ranked lower than
95% of the 364 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.94 vs. NYSE:GNC: 129.29 )
Ranked among companies with meaningful Days Inventory only.
NYSE:GNC' s Days Inventory Range Over the Past 10 Years
Min: 111.41  Med: 120.01 Max: 129.29
Current: 129.29
111.41
129.29
Days Sales Outstanding 17.89
NYSE:GNC's Days Sales Outstanding is ranked lower than
56% of the 279 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.07 vs. NYSE:GNC: 17.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
NYSE:GNC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 17.89  Med: 19.49 Max: 20.17
Current: 17.89
17.89
20.17
Days Payable 44.00
NYSE:GNC's Days Payable is ranked higher than
51% of the 276 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 43.87 vs. NYSE:GNC: 44.00 )
Ranked among companies with meaningful Days Payable only.
NYSE:GNC' s Days Payable Range Over the Past 10 Years
Min: 28.13  Med: 31.35 Max: 44
Current: 44
28.13
44

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 7.36
NYSE:GNC's Dividend Yield % is ranked higher than
97% of the 472 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.94 vs. NYSE:GNC: 7.36 )
Ranked among companies with meaningful Dividend Yield % only.
NYSE:GNC' s Dividend Yield % Range Over the Past 10 Years
Min: 0.27  Med: 1.46 Max: 10.47
Current: 7.36
0.27
10.47
3-Year Dividend Growth Rate 10.10
NYSE:GNC's 3-Year Dividend Growth Rate is ranked higher than
56% of the 185 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.40 vs. NYSE:GNC: 10.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NYSE:GNC' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 17.8
Current: 10.1
0
17.8
5-Year Yield-on-Cost % 7.36
NYSE:GNC's 5-Year Yield-on-Cost % is ranked higher than
85% of the 506 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.06 vs. NYSE:GNC: 7.36 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NYSE:GNC' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.27  Med: 1.46 Max: 10.47
Current: 7.36
0.27
10.47
3-Year Average Share Buyback Ratio 10.10
NYSE:GNC's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 210 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.70 vs. NYSE:GNC: 10.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NYSE:GNC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.1  Med: 7 Max: 0
Current: 10.1
-4.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.25
NYSE:GNC's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
97% of the 230 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.49 vs. NYSE:GNC: 0.25 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NYSE:GNC' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.22  Med: 0.72 Max: 1.97
Current: 0.25
0.22
1.97
Price-to-Median-PS-Value 0.15
NYSE:GNC's Price-to-Median-PS-Value is ranked higher than
98% of the 338 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. NYSE:GNC: 0.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NYSE:GNC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1 Max: 1.5
Current: 0.15
0.14
1.5
Price-to-Peter-Lynch-Fair-Value 0.25
NYSE:GNC's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 103 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.66 vs. NYSE:GNC: 0.25 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
NYSE:GNC' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 0.73 Max: 0.89
Current: 0.25
0
0.89
Earnings Yield (Greenblatt) % -10.67
NYSE:GNC's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.55 vs. NYSE:GNC: -10.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NYSE:GNC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.2  Med: 8.1 Max: 14.7
Current: -10.67
-11.2
14.7
Forward Rate of Return (Yacktman) % 43.47
NYSE:GNC's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 246 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.97 vs. NYSE:GNC: 43.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NYSE:GNC' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 21.7  Med: 24.2 Max: 43.47
Current: 43.47
21.7
43.47

More Statistics

Revenue (TTM) (Mil) $2,515.95
EPS (TTM) $ -4.47
Beta0.45
Short Percentage of Float51.24%
52-Week Range $6.51 - 28.11
Shares Outstanding (Mil)68.40

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,489 2,521 2,584
EPS ($) 1.53 1.65 1.76
EPS without NRI ($) 1.53 1.65 1.76
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}